Skip to main content
Clinical Trials/JPRN-UMIN000037090
JPRN-UMIN000037090
Completed
未知

Real world evidence of long-term safety and efficacy in patients treated with durvalumab after concurrent chemoradiation for unresectable stage III NSCLC ;AYAME study - Real world evidence of long-term safety and efficacy in patients treated with durvalumab after concurrent chemoradiation for unresectable stage III NSCLC ;AYAME study

AstraZeneca K.K.0 sites511 target enrollmentJune 17, 2019

Overview

Phase
未知
Intervention
Not specified
Conditions
nresectable stage III NSCLC
Sponsor
AstraZeneca K.K.
Enrollment
511
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 17, 2019
End Date
March 7, 2024
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Patients who would join PMS for durvalumab. Patients who would join any interventional clinical studies using unapproved drugs or off\-label use of drugs from the time of initial diagnosis to the end of the treatment of durvalmab. Age \< 20

Outcomes

Primary Outcomes

Not specified

Similar Trials